V souladu s legislativou České republiky poskytuje Společnost služby pouze kvalifikovaným investorům!

Talaris Therapeutics (TALS) Financial results for the second quarter of 2021.

12.08.2021

GAAP net loss is -$0.41, that is $0.18 worse than the same period last year.

Cash and cash equivalents are $266.2 million.